MedTrace Logo

Treatment of Hepatocellular Carcinoma With Radiofrequency Ablation (RFA) Associated With Postoperative TACE

NCT00730860 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 140

Last updated 2017-03-28

No results posted yet for this study

Summary

A RCT was conducted to elucidate whether the treatment outcome of HCC could be improved by RFA associated with postoperative TACE.

Conditions

  • Cancer of Liver

Interventions

PROCEDURE

radiofrequency ablation associated with TACE

treatment of hepatocellular carcinoma by radiofrequency ablation associated with postoperative transhepatic arterial chemoembolization

PROCEDURE

radiofrequency ablation only

treatment of hepatocellular carcinoma by radiofrequency ablation only

Sponsors & Collaborators

  • Agency for Science, Technology and Research

    collaborator OTHER

  • Southwest Hospital, China

    lead OTHER

Principal Investigators

  • Ma Kuansheng, Ph.D · Institute of hepatobiliary surgery,Southwest Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-12-31
Primary Completion
2018-01-30
Completion
2018-06-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00730860 on ClinicalTrials.gov